We are live on ! Find out more
PCRX icon

Pacira BioSciences

160 hedge funds and large institutions have $2.47B invested in Pacira BioSciences in 2014 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 57 increasing their positions, 47 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

290% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 10

75% more funds holding in top 10

Funds holding in top 10: 47 (+3)

72% more call options, than puts

Call options by funds: $11.1M | Put options by funds: $6.45M

22% more capital invested

Capital invested by funds: $2.02B → $2.47B (+$448M)

21% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 47

21% more funds holding

Funds holding: 132160 (+28)

Holders
160
Holders Change
+28
Holders Change %
+21.21%
% of All Funds
4.62%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.2%
New
39
Increased
57
Reduced
47
Closed
10
Calls
$11.1M
Puts
$6.45M
Net Calls
+$4.67M
Net Calls Change
-$1.53M
Name Holding Trade Value Shares
Change
Change in
Stake
SO
151
STRS Ohio
Ohio
$28K +$27.2K +400 New
PNC Financial Services Group
152
PNC Financial Services Group
Pennsylvania
$23K -$11.2K -164 -33%
VIA
153
Vantage Investment Advisors
Pennsylvania
$17K
CCS
154
Crosspoint Capital Strategies
California
$11K
PMFA
155
Plante Moran Financial Advisors
Michigan
$10K
KTC
156
Kistler-Tiffany Companies
Pennsylvania
$9K
WAS
157
Winch Advisory Services
Wisconsin
$7K +$6.8K +100 New
NES
158
New England Securities
New York
$4K +$4.08K +60 New
WTB
159
Washington Trust Bank
Washington
$3K +$3.4K +50 New
Manulife (Manufacturers Life Insurance)
160
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.47K -$10.1K -149 -0.7%
TCM
161
Tamarack Capital Management
California
-$4.31M -75,000 Closed
GE
162
General Electric
Ohio
-$1.4M -24,409 Closed
DILH
163
Dai-ichi Life Holdings
Japan
-$1.35M -23,465 Closed
Asset Management One
164
Asset Management One
Japan
-$534K -9,421 Closed
BTS
165
BB&T Securities
Virginia
-$2.05M -3,560 Closed
TRCT
166
Tower Research Capital (TRC)
New York
-$97K -1,682 Closed
BNP Paribas Financial Markets
167
BNP Paribas Financial Markets
France
-$20.5K -357 Closed
WA
168
Waverly Advisors
Alabama
-$11K -197 Closed
DADC
169
D.A. Davidson & Co
Montana
-$5K -100 Closed
SSG
170
Summit Securities Group
New York
-$3K -60 Closed

PCRX Hedge Fund Activity: Q1 2014 in Review

160 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q1 2014, worth a combined $2.47B — up 22% from $2.02B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new PCRX positions and 10 closed out — a net gain of 29 holders — while 57 added to existing stakes and 47 trimmed.

The largest buyer was Marsico Capital Management, adding an estimated $47.2M. The largest seller was AllianceBernstein, cutting an estimated $39M.

  • 160 institutional investors held Pacira BioSciences (PCRX) as of Q1 2014, up from 132 in Q4 2013.
  • Funds reported $2.47B of Pacira BioSciences stock for Q1 2014, up 22% quarter-over-quarter.
  • 39 funds opened new Pacira BioSciences positions in Q1 2014 and 10 closed out, a net change of +29 holders.
  • The largest Pacira BioSciences buyer in Q1 2014 was Marsico Capital Management, an estimated $47.2M added.
  • The largest Pacira BioSciences seller in Q1 2014 was AllianceBernstein, an estimated $39M sold.

Based on aggregated 13F filings for Q1 2014.